Global distribution of the CCR2-641/CCR5-59653T HIV-1 disease-protective haplotype
Date
2000Source
AIDSVolume
14Pages
483-489Google Scholar check
Keyword(s):
Metadata
Show full item recordAbstract
Objectives: Several natural polymorphisms in the genes for the human CC-chemokine receptors CCR5 and CCR2 are associated with HIV-1 disease. The CCR2-641 genetic variant [a G to A substitution resulting in a valine (V) to isoleucine (I) change at position 64] is in strong linkage disequilibrium with a mutation within the CCR5 regulatory region (CCR5-59653T). Individuals with two CCR2-641 alleles are not resistant to sexual transmission of HIV-1, but progress significantly more slowly to HIV-1 disease. It is therefore important to determine the global distributions of CCR2-641 and CCR5-59653T genetic variants and define the degree of linkage between them. Design and methods: We have developed molecular beacon-based, real-time PCR allele discrimination assays for all three chemokine receptor mutations, and used these spectral genotyping assays to genotype 3923 individuals from a globally distributed set of 53 populations. Results: CCR2-641 and CCR5-59653T genetic variants are found in almost all populations studied: their allele frequencies are greatest (~35%) in Africa and Asia but decrease in Northern Europe. We confirm that CCR2-641 is in strong linkage disequilibrium with CCR5-59653T (96.92% of individuals had the same genotype for both CCR2-641 and CCR5-59653T polymorphisms). Conclusions: The greater geographical distribution of the CCR2-641/CCR5-59653T haplotype compared with that of CCR5-Δ32 suggests that it is a much older mutation whose origin predates the dispersal of modern humans. (C) 2000 Lippincott Williams and Wilkins.
Collections
Cite as
Related items
Showing items related by title, author, creator and subject.
-
Article
Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: A translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial
Skarlos, P.; Christodoulou, C.; Kalogeras, K. T.; Eleftheraki, A. G.; Bobos, M.; Batistatou, Anna; Valavanis, C.; Tzaida, O.; Timotheadou, E.; Kronenwett, R.; Wirtz, R. M.; Kostopoulos, I.; Televantou, D.; Koutselini, E.; Papaspirou, I.; Papadimitriou, C.; Pectasides, Dimitrios; Gogas, H.; Aravantinos, Gerasimos; Pavlidis, Nicholas; Arapantoni, P.; Skarlos, Dimosthenis V.; Fountzilas, George (2012)Purpose: It is well recognized that breast cancer is a heterogeneous disease. The purpose of the current study was to classify patients according to the immunohistochemical phenotype of their tumors in an effort to evaluate ...
-
Article
Transcriptional activity of human epidermal growth factor receptor family and angiogenesis effectors in locoregionally recurrent head and neck squamous cell carcinoma and correlation with patient outcome
Pentheroudakis, George; Angouridakis, N.; Wirtz, R. M.; Nikolaou, A.; Kalogeras, K. T.; Pavlidis, Nicholas; Fountzilas, George (2009)Locoregional recurrence is the most common failure pattern in patients with head and neck squamous cell carcinoma (HNSCC). We retrospectively identified 41 HNSCC patients with locoregional relapse and used kinetic reverse ...
-
Article
Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms
Liu, J.; Burdette, J. E.; Xu, H.; Gu, C.; Van Breemen, R. B.; Bhat, K. P. L.; Booth, N.; Constantinou, Andreas I.; Pezzuto, J. M.; Fong, H. H. S.; Farnsworth, N. R.; Bolton, J. L. (2001)Eight botanical preparations that are commonly used for the treatment of menopausal symptoms were tested for estrogenic activity. Methanol extracts of red clover (Trifolium pratense L.), chasteberry (Vitex agnus-castus ...